Microvascular inflammation in kidney allografts has been widely reappraised in the recent update of Banff classification. There is a critical need to better understand the pathophysiological mechanisms associated with the various phenotypes of microvascular inflammation that are observed in kidney transplants, particularly in order to develop targeted therapeutic approaches.
Antibody-mediated rejection is a major cause of graft failure in kidney transplant recipients. The diagnostic criteria for antibody-mediated rejection have undergone significant changes since their initial definition in the international Banff Classification system. The Banff 2022 Classification update reappraises lesions of microvascular inflammation and identifies new phenotypes for cases with microvascular inflammation. However, pathophysiological mechanisms associated with microvascular inflammation in kidney allografts are still poorly understood, thus hampering the development of efficient treatments. The aims of this study are: 1. To decipher the spatial immune-molecular landscape of microvascular inflammation in kidney allografts. 2. To compare the characteristics of this landscape in different clinical scenarios. The investigators will use a multimodal phenotyping approach including histological analyses and multiplex immunostainings, bulk transcriptomic analyses and spatial whole-transcriptome digital profiling to decipher the molecular landscape of microvascular inflammation in kidney allografts. Based on these results, they will investigate its association with allograft outcomes and search for molecular targets which could benefit from targeted therapeutic strategies.
Study Type
OBSERVATIONAL
Enrollment
600
No intervention
Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France
RECRUITINGKidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France
RECRUITINGBichat Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France
RNA-based molecular signatures assessed using bulk and spatial transcriptomics
Time frame: 1 day (at time of a kidney allograft biopsy)
Probability of graft survival based on outcome data
Time frame: 24 months post-kidney allograft biopsy
Probability of patient survival on outcome data
Time frame: 24 months post-kidney allograft biopsy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.